Important Announcements

- 50% enrollment goal met in December, ahead of schedule
- We will be completing the enrollment and randomization phase of feasibility in the next few weeks!
- Subcontracting, IRB approval, and onboarding of full-scale sites will be starting in March.

Enrollment & Randomization Tracking

<table>
<thead>
<tr>
<th>322</th>
<th>268</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients Enrolled</td>
<td>Patients Randomized</td>
</tr>
</tbody>
</table>

Operational Updates

Protocol & Enrollment

- Collecting lessons learned to share with full-scale sites
- Feasibility protocol under review for publication at BMJ Open
- Clinician Education Resources available on MPOG website

Information Systems

- Developing automated operational metrics and reports
- thrivetrial.org informational website
- Continued refinement of data collection processes

Stakeholder Engagement

- Patient partner panel meeting Feb. 28th - qualitative research study, feedback from panel
- Patient End of Study survey IRB approved and in production
- Patient Partner Panel feedback request form

Timeline Update
The next major timepoints for the study include the end of feasibility and the beginning of full-scale.

Emerging & Relevant Literature

**VITAL**

**VOLATILE VS TOTAL INTRAVENOUS ANAESTHESIA FOR MAJOR NON-CARDIAC SURGERY**

**Ongoing trial comparing 30-day mortality and patient outcomes between patients receiving TIVA and inhaled volatile anesthesia**

The [Volatile vs Total Intravenous Anesthesia for Major Non-Cardiac Surgery (VITAL) study](#) is an ongoing trial testing whether total intravenous anesthesia (TIVA) is better than inhalational anesthesia for patients undergoing major non-cardiac surgery in the NHS (UK).

The objectives of the trial include days alive and at home at 30 days post surgery, survival and quality of recovery amongst patients. Like THRIVE, the VITAL research team is also evaluating the safety of TIVA, in particular accidental awareness under anesthesia.

Suggestion Box

Are our newsletters informative? Could they be better?

Tell us how we're doing!

[Complete the Google Form here](#).